Researchers developed and validated a highly sensitive method to measure the soy-derived peptide lunasin in blood, then confirmed it is absorbed after oral consumption in rabbits.
34.6 ng/mL detection limitSensitive enough to measure lunasin in blood after oral consumption of soy-based food in rabbits
What the researchers found
A validated UPLC-Q-ToF/MS method was developed with an LLOQ of 34.6 ng/mL and linearity from 35–10,000 ng/mL. Accuracy ranged from 86.7% to 88.9% recovery, with intraday precision <2.65% RSD and interday precision <6.22% RSD. The method was successfully applied to a pharmacokinetic study in rabbits given oral lunasin-rich processed soybeans at two doses (6.56 and 19.1 g/kg), confirming oral bioavailability of lunasin.
Why it matters
Lunasin has been studied for potential anti-cancer, anti-inflammatory, and cholesterol-lowering effects, but its clinical potential depends on whether it survives digestion and reaches the bloodstream. This study provides both the measurement tools and preliminary evidence that oral lunasin is bioavailable — a critical step toward understanding its therapeutic potential.
How the study worked
The analytical method was developed using design of experiments (DoE) methodology to optimize UPLC-Q-ToF/MS conditions. Separation used a BEH-C18 column with a 9-minute gradient. Neuropeptide Y served as the internal standard. The method was validated for accuracy, precision, linearity, and sensitivity, then applied to a pharmacokinetic study with oral lunasin administration to rabbits.
What this study cannot tell us
The pharmacokinetic study was conducted in rabbits, and absorption patterns may differ in humans. Only processed soybean-derived lunasin was tested, not purified peptide. The abstract does not report specific PK parameters (Cmax, Tmax, AUC, half-life), limiting interpretation of the absorption profile. The sample size for the PK study was not specified.
How to read the evidence
This is a methods development paper with a preliminary animal pharmacokinetic application. While the analytical validation is rigorous, the PK findings are from a small rabbit study with limited reported parameters.
When this study was published
Published in 2025, this represents recent progress in characterizing the oral bioavailability of food-derived bioactive peptides.
The bigger picture
Food-derived bioactive peptides are a growing area of nutraceutical research. The challenge with many of these peptides is proving they actually reach the bloodstream in meaningful amounts after oral consumption. This validated method and PK data for lunasin contribute to the broader effort to bridge the gap between in vitro peptide activity and real-world bioavailability.
Questions still open
- What are the actual pharmacokinetic parameters (peak levels, half-life) of orally consumed lunasin?
- Does lunasin achieve blood concentrations in humans sufficient to produce the biological effects seen in cell studies?
- How does food processing affect lunasin bioavailability compared to purified peptide supplements?
Common questions
What is lunasin and why is it interesting?
Does this mean eating soybeans delivers lunasin to your body?
Read the original research
Design of Experiments Approach for the Development of a Validated UPLC-Q-ToF/MS Method to Quantitate Soy-Derived Bioactive Peptide Lunasin in Rabbit Plasma: Application to a Pharmacokinetic Study.
Biomedical chromatography : BMC, 39(6), e70098
Citation
Kowmudi, Gullapalli; Anoop, Karthika; Varshini, Magham Sai; Nagappan, Krishnaveni; Konanki, Sreenath; Praveen, Thaggikuppe Krishnamurthy. (2025). Design of Experiments Approach for the Development of a Validated UPLC-Q-ToF/MS Method to Quantitate Soy-Derived Bioactive Peptide Lunasin in Rabbit Plasma: Application to a Pharmacokinetic Study.. Biomedical chromatography : BMC, 39(6), e70098. https://doi.org/10.1002/bmc.70098